98 related articles for article (PubMed ID: 8297104)
21. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II.
Hasinoff BB; Wu X; Begleiter A; Guziec LJ; Guziec F; Giorgianni A; Yang S; Jiang Y; Yalowich JC
Cancer Chemother Pharmacol; 2006 Jan; 57(2):221-33. PubMed ID: 16010589
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
23. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
24. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
Harris LN; Yang L; Liotcheva V; Pauli S; Iglehart JD; Colvin OM; Hsieh TS
Clin Cancer Res; 2001 Jun; 7(6):1497-504. PubMed ID: 11410482
[TBL] [Abstract][Full Text] [Related]
25. Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells.
Lage H; Dietel M
J Cancer Res Clin Oncol; 2002 Jul; 128(7):349-57. PubMed ID: 12136248
[TBL] [Abstract][Full Text] [Related]
26. The dietary anticancer agent ellagic acid is a potent inhibitor of DNA topoisomerases in vitro.
Constantinou A; Stoner GD; Mehta R; Rao K; Runyan C; Moon R
Nutr Cancer; 1995; 23(2):121-30. PubMed ID: 7644381
[TBL] [Abstract][Full Text] [Related]
27. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
28. B1, a novel topoisomerase II inhibitor, induces apoptosis and cell cycle G1 arrest in lung adenocarcinoma A549 cells.
Cheng MH; Yang YC; Wong YH; Chen TR; Lee CY; Yang CC; Chen SH; Yang IN; Yang YS; Huang HS; Yang CY; Huang MS; Chiu HF
Anticancer Drugs; 2012 Feb; 23(2):191-9. PubMed ID: 22008852
[TBL] [Abstract][Full Text] [Related]
29. Treatment of U937 cells with bufalin induces the translocation of casein kinase 2 and modulates the activity of topoisomerase II prior to the induction of apoptosis.
Watabe M; Nakajo S; Yoshida T; Kuroiwa Y; Nakaya K
Cell Growth Differ; 1997 Aug; 8(8):871-9. PubMed ID: 9269896
[TBL] [Abstract][Full Text] [Related]
30. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Camara J; Kasprzyk PG; Prévost G; Bigg DC
Cancer Res; 2004 Jul; 64(14):4942-9. PubMed ID: 15256467
[TBL] [Abstract][Full Text] [Related]
31. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
32. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
33. Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II.
Li Y; Luan Y; Qi X; Li M; Gong L; Xue X; Wu X; Wu Y; Chen M; Xing G; Yao J; Ren J
Toxicol Sci; 2010 Dec; 118(2):435-43. PubMed ID: 20855424
[TBL] [Abstract][Full Text] [Related]
34. Topoisomerase II alpha and beta in human tumor cells grown in vitro and in vivo.
Prosperi E; Sala E; Negri C; Oliani C; Supino R; Astraldi Ricotti GB; Bottiroli G
Anticancer Res; 1992; 12(6B):2093-9. PubMed ID: 1338275
[TBL] [Abstract][Full Text] [Related]
35. Chinese hamster ovary cells resistant to okadaic acid express a multidrug resistant phenotype.
Tohda H; Yasui A; Yasumoto T; Nakayasu M; Shima H; Nagao M; Sugimura T
Biochem Biophys Res Commun; 1994 Sep; 203(2):1210-6. PubMed ID: 7916570
[TBL] [Abstract][Full Text] [Related]
36. Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.
de Jong S; Zijlstra JG; Mulder NH; de Vries EG
Cancer Chemother Pharmacol; 1991; 28(6):461-4. PubMed ID: 1657425
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of topoisomerase I activity by tyrphostin derivatives, protein tyrosine kinase blockers: mechanism of action.
Aflalo E; Iftach S; Segal S; Gazit A; Priel E
Cancer Res; 1994 Oct; 54(19):5138-42. PubMed ID: 7923131
[TBL] [Abstract][Full Text] [Related]
38. Suramin rapidly alters cellular tyrosine phosphorylation in prostate cancer cell lines.
Sartor O; McLellan CA; Myers CE; Borner MM
J Clin Invest; 1992 Dec; 90(6):2166-74. PubMed ID: 1281826
[TBL] [Abstract][Full Text] [Related]
39. [The effect of suramin on human lung cancer cell line in vitro].
Fujiuchi S; Tsuji T; Ohsaki Y; Kikuchi K
Gan To Kagaku Ryoho; 1994 Apr; 21(5):647-52. PubMed ID: 8154891
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of DNA topoisomerase II alpha and II beta genes between small cell and non-small cell lung cancer.
Syahruddin E; Oguri T; Takahashi T; Isobe T; Fujiwara Y; Yamakido M
Jpn J Cancer Res; 1998 Aug; 89(8):855-61. PubMed ID: 9765623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
